Benzinga | Aug 23, 2021 07:35AM EDT

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer's Disease Summit

Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer's drug development, and the utility of ERP P300 in Athira's Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer's Disease Summit taking place virtually August 24-26, 2021.